Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: OTC US
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

GW Pharmaceuticals PLC

+ Add to Watchlist

GWPRF:US

0.7400 USD 0.0200 2.78%

As of 20:10:00 ET on 05/24/2013.

Company Profile for GW Pharmaceuticals PLC (GWPRF)

GW Pharmaceuticals plc researches and develops cannabinoid prescription medicines for the treatment of cancer pain, Multiple Sclerosis, and neuropathic pain.

Contact Information

GW Pharmaceuticals PLC

Porton Down Science Park
Salisbury
Wiltshire, SP4 0JQ
United Kingdom
Phone: 44-19-8055-7000
Fax: 44-19-8055-7111

Key Executives for GW Pharmaceuticals PLC (GWPRF)

Geoffrey William GuyChairman/FounderJustin David GoverChief Executive Officer
Adam David GeorgeCFO/SecretaryChristopher John Tovey "Chris"Chief Operating Officer
Alice MeadVP:US Professional RelationsStephen D SchultzVP:Investor Relations
Stephen WrightDirector:Research & DevMarilyn EmeryDirector:Quality
Peter GibsonDirector:TechnicalManuel LouredaDirector:Manufacturing Ops
Roger PertweeDirector:PharmacologyDavid PotterDirector:Botanical Research
Richard PottsDirector:Clinical OperationsColin StottDirector:Research & Dev Ops
Alison ThompsonDirector:Regulatory AffairsPaul PritchardDirector:Supply Chain
Philip RobsonDirector:CannabinoidRenuka SoleyManager:Sativex Global Bus

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil